Fig. 1From: Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort studyIdentification of trials reviewed by the FDA for New Drug Applications with neuropsychiatric indications, 2005–2014. Flow chart depicting the process of selecting efficacy trials conducted to support new neuropsychiatric drugs and reviewed by the FDA for drug approval between 2005 and 2014. Trials can be excluded for satisfying one or more exclusion criteriaBack to article page